HC Wainwright Issues Pessimistic Forecast for KROS Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – HC Wainwright lowered their FY2024 EPS estimates for Keros Therapeutics in a report issued on Thursday, November 7th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($5.36) for the year, down from their prior estimate of ($4.64). HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($5.14) per share. HC Wainwright also issued estimates for Keros Therapeutics’ Q4 2024 earnings at ($1.48) EPS, Q1 2025 earnings at ($1.51) EPS, Q2 2025 earnings at ($1.57) EPS, Q3 2025 earnings at ($1.54) EPS, Q4 2025 earnings at ($1.59) EPS, FY2025 earnings at ($6.21) EPS, FY2026 earnings at ($7.15) EPS, FY2027 earnings at ($8.41) EPS and FY2028 earnings at ($5.79) EPS.

A number of other equities analysts have also commented on the stock. Guggenheim began coverage on shares of Keros Therapeutics in a research report on Monday, September 23rd. They set a “buy” rating and a $96.00 price target on the stock. Jefferies Financial Group initiated coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating on the stock. Scotiabank initiated coverage on shares of Keros Therapeutics in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price on the stock. Wedbush reissued an “outperform” rating and issued a $84.00 target price on shares of Keros Therapeutics in a report on Thursday, November 7th. Finally, Cantor Fitzgerald initiated coverage on shares of Keros Therapeutics in a report on Thursday, October 24th. They issued an “overweight” rating on the stock. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $88.89.

Keros Therapeutics Stock Performance

NASDAQ:KROS opened at $64.88 on Monday. Keros Therapeutics has a 52 week low of $27.31 and a 52 week high of $73.00. The firm has a market cap of $2.43 billion, a price-to-earnings ratio of -13.08 and a beta of 1.23. The firm’s 50-day simple moving average is $58.65 and its 200 day simple moving average is $52.23.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million for the quarter. During the same quarter last year, the company posted ($1.33) earnings per share. The business’s revenue for the quarter was up 4750.0% compared to the same quarter last year.

Institutional Investors Weigh In On Keros Therapeutics

Hedge funds have recently made changes to their positions in the stock. KBC Group NV boosted its stake in shares of Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares in the last quarter. Values First Advisors Inc. acquired a new stake in shares of Keros Therapeutics in the 3rd quarter valued at approximately $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Keros Therapeutics in the 2nd quarter valued at approximately $128,000. Finally, Ameritas Investment Partners Inc. boosted its stake in shares of Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after purchasing an additional 324 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.